Within the last decade there has been an explosion of new therapeutic options for people suffering from rheumatoid arthritis. The challenge is to identify those patients that will respond to classical drug regimes, and those that need to go directly on to the newer therapeutic options. We will discuss exciting precision medicine research from the University of Glasgow that aims to identify “biomarkers” for the stratification of patients to the treatment that they are most likely to respond to. We aim to remove elements of ‘trial and error’ from treatment in favour of more precise medicine.

• View event on Facebook
• View event on Meetup

* No tickets required … just show up!

About the speaker:
Professor Carl Goodyear studied molecular biology at the University of Glasgow and graduated with honours. He then gained a PhD in molecular immunology. Upon completing his PhD, he moved to the US and worked in the Department of Medicine at the University of California at San Diego where he eventually held the position of Assistant Professor. During this period, he was awarded a Cancer Research Institute Postdoctoral Fellowship, became a National Blood Foundation Scholar, and received several awards including the National Blood Foundation David B. Pall Prize for Innovative Research in Transfusion Medicine and an Arthritis Foundation Investigator Award. In 2006 he was awarded a prestigious Arthritis Research UK Fellowship and returned to work in the UK at the Institute of Infection Immunity and Inflammation in the University of Glasgow.

His research is currently focused on understanding immunopathogenesis of disease (i.e., Rheumatoid Arthritis & Osteoarthritis) and translating this knowledge into viable therapeutic agents for patients. He leads a Translational Immunology programme that provides the critical interface between clinical and basic science, with a specific focus on precision medicine. In parallel, he is also the Director of the GLAZgo Discovery Centre, a collaboration between the University of Glasgow and AstraZeneca to drive innovative academic/industry research. Professor Goodyear has published widely in the areas of immunobiology and rheumatology. He was elected a fellow of the Royal Society of Biology in 2016 and is a Visiting Research Fellow at the University of Birmingham, University of Newcastle and Visiting Professor at the University of the West of Scotland.

Doors at 7.15, kickoff at 7.30
This is event is free to attend, although we will be asking for donations at the end of the talk. Participants are under no obligation whatsoever to donate, however please rest assured that the money we collect doesn’t end up in anyone’s pocket – it is used to fund our overhead costs, and travel/accommodation for our speakers who come from further afield.

Accessibility: As per the policy of the Admiral Bar, access to the venue “can only be provided to patrons who are sufficiently mobile and capable of independently evacuating premises, or with the minimum of assistance”. Unfortunately, this leaves the basement inaccessible to most wheelchair users.